Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of IPX203 in Parkinson's disease patients with motor fluctuations
2018-002234-21Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by Impax Laboratories. Primary endpoint: Safety endpoints. Started May 2019; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-002234-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002234-21.